2vtr › Citations

Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.

Wyatt PG, Woodhead AJ, Berdini V, Boulstridge JA, Carr MG, Cross DM, Davis DJ, Devine LA, Early TR, Feltell RE, Lewis EJ, McMenamin RL, Navarro EF, O'Brien MA, O'Reilly M, Reule M, Saxty G, Seavers LC, Smith DM, Squires MS, Trewartha G, Walker MT, Woolford AJ
J Med Chem 51 4986-99 (2008)
Related entries: 2vta, 2vth, 2vti, 2vtj, 2vtl, 2vtm, 2vtn, 2vto, 2vtp, 2vtq, 2vts, 2vtt, 2vu3

Cited: 125 times
EuropePMC logo PMID: 18656911

Abstract

The application of fragment-based screening techniques to cyclin dependent kinase 2 (CDK2) identified multiple (>30) efficient, synthetically tractable small molecule hits for further optimization. Structure-based design approaches led to the identification of multiple lead series, which retained the key interactions of the initial binding fragments and additionally explored other areas of the ATP binding site. The majority of this paper details the structure-guided optimization of indazole (6) using information gained from multiple ligand-CDK2 cocrystal structures. Identification of key binding features for this class of compounds resulted in a series of molecules with low nM affinity for CDK2. Optimisation of cellular activity and characterization of pharmacokinetic properties led to the identification of 33 (AT7519), which is currently being evaluated in clinical trials for the treatment of human cancers.

Articles - 2vtr mentioned but not cited (3)

  1. Prediction of cyclin-dependent kinase 2 inhibitor potency using the fragment molecular orbital method. Mazanetz MP, Ichihara O, Law RJ, Whittaker M. J Cheminform 3 2 (2011)
  2. Structure-based predictions of activity cliffs. Husby J, Bottegoni G, Kufareva I, Abagyan R, Cavalli A. J Chem Inf Model 55 1062-1076 (2015)
  3. BIO-GATS: A Tool for Automated GPCR Template Selection Through a Biophysical Approach for Homology Modeling. Jabeen A, Vijayram R, Ranganathan S. Front Mol Biosci 8 617176 (2021)


Reviews citing this publication (34)

  1. Targeting cancer with small molecule kinase inhibitors. Zhang J, Yang PL, Gray NS. Nat Rev Cancer 9 28-39 (2009)
  2. Cell cycle proteins as promising targets in cancer therapy. Otto T, Sicinski P. Nat Rev Cancer 17 93-115 (2017)
  3. The Halogen Bond. Cavallo G, Metrangolo P, Milani R, Pilati T, Priimagi A, Resnati G, Terraneo G. Chem Rev 116 2478-2601 (2016)
  4. The rise of fragment-based drug discovery. Murray CW, Rees DC. Nat Chem 1 187-192 (2009)
  5. The influence of lipophilicity in drug discovery and design. Arnott JA, Planey SL. Expert Opin Drug Discov 7 863-875 (2012)
  6. Inhibitors of cyclin-dependent kinases as cancer therapeutics. Whittaker SR, Mallinger A, Workman P, Clarke PA. Pharmacol Ther 173 83-105 (2017)
  7. Protein kinase inhibitors: contributions from structure to clinical compounds. Johnson LN. Q Rev Biophys 42 1-40 (2009)
  8. Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Peyressatre M, Prével C, Pellerano M, Morris MC. Cancers (Basel) 7 179-237 (2015)
  9. Halogen bonding (X-bonding): a biological perspective. Scholfield MR, Zanden CM, Carter M, Ho PS. Protein Sci 22 139-152 (2013)
  10. Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present. Casimiro MC, Velasco-Velázquez M, Aguirre-Alvarado C, Pestell RG. Expert Opin Investig Drugs 23 295-304 (2014)
  11. Structural biology in fragment-based drug design. Murray CW, Blundell TL. Curr Opin Struct Biol 20 497-507 (2010)
  12. Cyclin dependent kinases in cancer: potential for therapeutic intervention. Canavese M, Santo L, Raje N. Cancer Biol Ther 13 451-457 (2012)
  13. From fragment to clinical candidate--a historical perspective. Chessari G, Woodhead AJ. Drug Discov Today 14 668-675 (2009)
  14. Transforming fragments into candidates: small becomes big in medicinal chemistry. de Kloe GE, Bailey D, Leurs R, de Esch IJ. Drug Discov Today 14 630-646 (2009)
  15. The influence of the 'organizational factor' on compound quality in drug discovery. Leeson PD, St-Gallay SA. Nat Rev Drug Discov 10 749-765 (2011)
  16. Cyclin-dependent kinase inhibitors: a survey of recent patent literature. Galons H, Oumata N, Meijer L. Expert Opin Ther Pat 20 377-404 (2010)
  17. Lessons from Hot Spot Analysis for Fragment-Based Drug Discovery. Hall DR, Kozakov D, Whitty A, Vajda S. Trends Pharmacol Sci 36 724-736 (2015)
  18. Targeting CDK9 for Anti-Cancer Therapeutics. Mandal R, Becker S, Strebhardt K. Cancers (Basel) 13 2181 (2021)
  19. X-ray crystallography over the past decade for novel drug discovery - where are we heading next? Zheng H, Handing KB, Zimmerman MD, Shabalin IG, Almo SC, Minor W. Expert Opin Drug Discov 10 975-989 (2015)
  20. NMR as a "Gold Standard" Method in Drug Design and Discovery. Emwas AH, Szczepski K, Poulson BG, Chandra K, McKay RT, Dhahri M, Alahmari F, Jaremko L, Lachowicz JI, Jaremko M. Molecules 25 E4597 (2020)
  21. Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC). Wijnen R, Pecoraro C, Carbone D, Fiuji H, Avan A, Peters GJ, Giovannetti E, Diana P. Cancers (Basel) 13 4389 (2021)
  22. The Role of CDK5 in Tumours and Tumour Microenvironments. Do PA, Lee CH. Cancers (Basel) 13 E101 (2020)
  23. Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors. Sharma S, Singh J, Ojha R, Singh H, Kaur M, Bedi PMS, Nepali K. Eur J Med Chem 112 298-346 (2016)
  24. Library screening by fragment-based docking. Huang D, Caflisch A. J Mol Recognit 23 183-193 (2010)
  25. Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of central nervous system diseases. Liu DZ, Ander BP, Sharp FR. Neurobiol Dis 37 549-557 (2010)
  26. NMR-Fragment Based Virtual Screening: A Brief Overview. Singh M, Tam B, Akabayov B. Molecules 23 E233 (2018)
  27. Recent advances on CDK inhibitors: An insight by means of in silico methods. Tutone M, Almerico AM. Eur J Med Chem 142 300-315 (2017)
  28. Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update. Liu DZ, Ander BP. ScientificWorldJournal 2012 491737 (2012)
  29. The role of protein structural analysis in the next generation sequencing era. Yue WW, Froese DS, Brennan PE. Top Curr Chem 336 67-98 (2014)
  30. Biased and unbiased strategies to identify biologically active small molecules. Abet V, Mariani A, Truscott FR, Britton S, Rodriguez R. Bioorg Med Chem 22 4474-4489 (2014)
  31. CDK9 inhibitors in cancer research. Huang Z, Wang T, Wang C, Fan Y. RSC Med Chem 13 688-710 (2022)
  32. Maintaining Genome Stability in Defiance of Mitotic DNA Damage. Ferrari S, Gentili C. Front Genet 7 128 (2016)
  33. [Fragment-based drug discovery: concept and aim]. Tanaka D. Yakugaku Zasshi 130 315-323 (2010)
  34. Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress. Liu Y, Li C, Liu H, Tan S. Arch Pharm Res (2024)

Articles citing this publication (88)



Quick links